Relevant research showed, trametinib combined with PI3K/mTOR dual inhibitor dactylitis can eliminate the enhancement of nuclear receptor related-1 protein (Nurr1) to cervical cancer cell aggressiveness by upregulating p21 and p27 expression and inhibiting MMP9 and KLF4 expression (Wan et al., 2021). Here, KLF4 is linked to cervical cancer.